Preservation of renal function during gout treatment with febuxostat: A quantitative study

Andrew Whelton, Patricia A. MacDonald, Solomon Chefo, Lhanoo Gunawardhana

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Hyperuricemia can accelerate renal decline associated with aging. Chronic kidney disease is frequently seen in patients with hyperuricemia and gout. Objectives: Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤48 months. Methods: Subjects from 2 phase 3 clinical studies were enrolled in the phase 3, long-term, open-label Febuxostat/Allopurinol Comparative Extension Long-Term (EXCEL) study. In the EXCEL study, 1086 subjects initially were treated with febuxostat 80 or 120 mg daily, or allopurinol 300 mg daily. The subjects were permitted to switch between doses of febuxostat and/or allopurinol during the first 6 months of treatment to achieve and maintain a serum uric acid (SUA) level ≥ 3 to

Original languageEnglish (US)
Pages (from-to)106-114
Number of pages9
JournalPostgraduate Medicine
Volume125
Issue number1
DOIs
StatePublished - Jan 2013

Keywords

  • Febuxostat
  • Gout
  • Hyperuricemia
  • Renal function
  • Serum uric acid

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Preservation of renal function during gout treatment with febuxostat: A quantitative study'. Together they form a unique fingerprint.

Cite this